

INIM0031: Neoplasia and its Treatment

[View Online](#)

-
1.
Weinberg, R. A. The biology of cancer. (Garland Science, 2014).
 2.
Hanahan, D. & Weinberg, R. A. The Hallmarks of Cancer. Cell **100**, 57–70 (2000).
 3.
Lazebnik, Y. What are the hallmarks of cancer? Nature Reviews Cancer **10**, 232–233 (2010).
 4.
Jeggo, P. A., Pearl, L. H. & Carr, A. M. DNA repair, genome stability and cancer: a historical perspective. Nature Reviews Cancer **16**, 35–42 (2015).
 5.
Roos, W. P., Thomas, A. D. & Kaina, B. DNA damage and the balance between survival and death in cancer biology. Nature Reviews Cancer **16**, 20–33 (2015).
 6.
Shankaran, V. et al. IFN γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature **410**, 1107–1111 (2001).

7.

Koebel, C. M. et al. Adaptive immunity maintains occult cancer in an equilibrium state. *Nature* **450**, 903–907 (2007).

8.

Hodi, F. S. et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. *New England Journal of Medicine* **363**, 711–723 (2010).

9.

Robert D. Schreiber, Lloyd J. Old and Mark J. Smyth. Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion. *Science* **331**, 1565–1570 (2011).

10.

Topalian, S. L. et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. *New England Journal of Medicine* **366**, 2443–2454 (2012).

11.

Grupp, S. A. et al. Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia. *New England Journal of Medicine* **368**, 1509–1518 (2013).

12.

Robbins, P. F. et al. Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. *Journal of Clinical Oncology* **29**, 917–924 (2011).

13.

Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. *Science* **348**, 69–74 (2015).

14.

Klebanoff, C. A., Rosenberg, S. A. & Restifo, N. P. Prospects for gene-engineered T cell immunotherapy for solid cancers. *Nature Medicine* **22**, 26–36 (2016).

15.

Morris, E. C. & Stauss, H. J. Optimizing T-cell receptor gene therapy for hematologic malignancies. *Blood* **127**, 3305–3311 (2016).

16.

de Martel, C. et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. *The Lancet Oncology* **13**, 607–615 (2012).

17.

zur Hausen, H. Papillomaviruses in the causation of human cancers — a brief historical account. *Virology* **384**, 260–265 (2009).

18.

Ajila, V., Shetty, H., Babu, S., Shetty, V. & Hegde, S. Human Papilloma Virus Associated Squamous Cell Carcinoma of the Head and Neck. *Journal of Sexually Transmitted Diseases* **2015**, 1–5 (2015).

19.

Spurgeon, M. E. & Lambert, P. F. Merkel cell polyomavirus: A newly discovered human virus with oncogenic potential. *Virology* **435**, 118–130 (2013).

20.

Wendzicki, J. A., Moore, P. S. & Chang, Y. Large T and small T antigens of Merkel cell polyomavirus. *Current Opinion in Virology* **11**, 38–43 (2015).

21.

Schinzari, V., Barnaba, V. & Piconese, S. Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors. *Clinical Microbiology and*

Infection **21**, 969–974 (2015).

22.

Lingyun Geng. Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments. *International Journal of Clinical and Experimental Medicine* **8**, (2015).

23.

Weiss, R. A. & Vogt, P. K. 100 years of Rous sarcoma virus. *The Journal of Experimental Medicine* **208**, 2351–2355 (2011).

24.

Matsuoka, M. & Jeang, K.-T. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. *Oncogene* **30**, 1379–1389 (2011).

25.

Pierangeli, A., Antonelli, G. & Gentile, G. Immunodeficiency-associated viral oncogenesis. *Clinical Microbiology and Infection* **21**, 975–983 (2015).

26.

Reichert, J. M. Antibodies to watch in 2017. *mAbs* **9**, 167–181 (2017).

27.

Reichert, J. M. Antibodies to watch in 2016. *mAbs* **8**, 197–204 (2016).

28.

Ecker, D. M., Jones, S. D. & Levine, H. L. The therapeutic monoclonal antibody market. *mAbs* **7**, 9–14 (2015).

29.

Reichert, J. M. Marketed therapeutic antibodies compendium. *mAbs* **4**, 413–415 (2012).

30.

Varghese, S. & Rabkin, S. D. Oncolytic herpes simplex virus vectors for cancer virotherapy. *Cancer Gene Therapy* **9**, 967–978 (2002).

31.

Russell, S. J., Peng, K.-W. & Bell, J. C. Oncolytic virotherapy. *Nature Biotechnology* **30**, 658–670 (2012).

32.

Kaufman, H. L., Kohlhapp, F. J. & Zloza, A. Oncolytic viruses: a new class of immunotherapy drugs. *Nature Reviews Drug Discovery* **14**, 642–662 (2015).

33.

Larson, C. et al. Going viral: a review of replication-selective oncolytic adenoviruses. *Oncotarget* **6**, (2015).

34.

Restifo, N. P., Dudley, M. E. & Rosenberg, S. A. Adoptive immunotherapy for cancer: harnessing the T cell response. *Nature Reviews Immunology* **12**, 269–281 (2012).

35.

Gill, S. & June, C. H. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. *Immunological Reviews* **263**, 68–89 (2015).

36.

Barrett, D. M., Grupp, S. A. & June, C. H. Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street. *The Journal of Immunology* **195**, 755–761 (2015).

37.

Palucka, K. & Banchereau, J. Cancer immunotherapy via dendritic cells. *Nature Reviews Cancer* **12**, 265–277 (2012).